- Adding consolidative thoracic radiation therapy (TRT) to chemotherapy significantly improves survival in patients with extensive-stage small-cell lung cancer (SCLC).
- Patients who received >10 radiation treatments had better OS than those who received fewer treatments.
Why this matters
- Studies on the survival benefit of adding TRT to the standard regimen of platinum-based chemotherapy have yielded conflicting results, and the regimen remains underutilized.
- 14,367 patients with extensive-stage SCLC from the National Cancer Database.
- Funding: None disclosed.
- 83.7% received CT alone and 16.3% received TRT after CT.
- OS with TRT+CT was better than CT alone at 12 months (47.7% vs 25.0%) and 5 years (7.1% vs 2.0%).
- TRT+CT was associated with improved OS compared with CT alone (HR, 1.74; P<.001>
- OS advantage remained after propensity matching (HR, 1.80; P<.001>
- Receiving >10 radiation treatments was associated with improved OS before (HR, 1.42; P<.001 and after p propensity matching.>
- Retrospective study.